

Barcelona, March 21, 2017

PRESS RELEASE

BIONURE BREAKS THE RECORDS RAISING MORE THAN €1M

Highlights

- Capital Cell's crowdfunding campaign - Bionure - overfunds with more than €1M and becomes Spain's largest ever life science equity crowdfunding campaign.
- With this campaign Bionure will now be able to take the next imperative step and begin promising phase-I clinical trials for their novel first-in-class drug for the treatment of multiple sclerosis.
- Following the success of Capital Cell in its country of origin, Spain, with a series of fantastic biotechnology projects funded, the company is currently in the pre-launch phase of expanding into the UK market.
- Capital Cell will be officially launching the new platform at the end of April in association with their partners, the life science angel syndicate group Angels in MedCity

Details

Huge congratulations are in order for Bionure, a biotech company developing a novel first-in-class drug for the treatment of multiple sclerosis, who are currently overfunding on the Capital Cell crowdfunding platform. With more than €1M raised, this campaign is breaking records by becoming the largest amount raised on a life science equity crowdfunding platform to date, in Spain. Valued at 9,400,000€ and with an estimated ROI of 1400%, Bionure is now at 110% of its funding goal and keeps on rising.

The capital raised from over 240 investors sharing 9.27% equity in the business will be used by the company to develop BN201, a promising first-in-class drug candidate to halt the development of multiple sclerosis. This disease affects about 2.5 million people worldwide and more than 600,000 in Europe. To date there is no cure.

This new drug acts as a neuroprotector, preventing the nervous system from damage and reversing the detrimental effects of multiple sclerosis disease. At present, there is no other drug with this dual role of neuroprotection and regeneration, making BN201 a unique product and a hope to multiple sclerosis patients, but also other neurodegenerative diseases such as Parkinsons and Alzheimers.

After more than six years of research, this late-preclinical drug development company based in Barcelona and California will now be able to take the next big and imperative step: to complete their preclinical phase and begin the BN201 promising phase-I clinical trials.

As happens with many of the projects raising funds with Capital Cell, Bionure's campaign '#estamosaesto' ('we are this close') is capturing the interest of an heterogeneous 'crowd' of investors: from multiple sclerosis patients, relatives and friends, to accredited investors attracted by both the high social impact and the impressive business opportunity it represents (the estimated market for BN201 is about €1.2 billion). "The Capital Cell platform is a great way to expand funding possibilities, reaching investors that we would had never been able to reach", argues Albert G. Zamora, Bionure CEO.

Capital Cell UK Launch

“This is a fantastic representation of Capital Cell as a reputable equity investment platform, in the run up to our UK Launch” says Daniel Oliver, Capital Cell CEO. Following the success of Capital Cell in its country of origin, Spain, the company is currently in the pre-launch phase of expanding into the UK market. “We’re showcasing some amazing, innovative scientific research projects, and giving smaller companies the opportunity to make big changes in the world of life science. Capital Cell provides investors at all levels with the opportunity to not only directly fund companies that can change lives, but also invest in one of the most profitable sectors around”, adds Laura Ferguson, UK Director.

As the first European equity investment platform to specialise in the life science industry, Capital Cell has already celebrated some fantastic achievements in Spain. To date, the platform has successfully closed 13 fundraising campaigns, helping to raise almost €4 million for life science projects, from more than 550 individual investors. Three further campaigns are currently in process, including Bionure, and several promising ones are in the pipeline.

With the UK launch, Capital Cell aims to become the investment platform of reference for biotechnology, drug discovery, medical devices and therapeutics companies in Europe. ‘Considering leading role of the UK in both equity crowdfunding and life science innovation, it was the logical place for Capital Cell to grow. Cambridge, as the widely considered life science hub of the country, is the perfect place to set our UK headquarters’, reveals Daniel.

Capital Cell’s UK web platform will be launching on 26th March 2017, with an official launch appearance on 26th April as part of the Angels in MedCity company pitching event in London.

Additional Information

For more information about Bionure’s crowdfunding campaign:

[Bionure on Capital Cell](#)

[Bionure website](#)

[Bionure promotional video campaign](#)

For more information about Capital Cell:

[Capital Cell website](#)

Contact Information

Katie Anderton

Head of Marketing

Capital Cell

Office 2D2, Plaça de Pau Vila, 1, 08039 (Barcelona), Spain

T: +34 931 00 42 87

E: katie@capitalcell.net

www.capitalcell.net

About Capital Cell

Capital Cell is the first pan-European crowdinvesting platform for biotech & Life Sciences companies. Mixing VC, business angels, accredited investors and the power of the Crowd, we are building a global meeting point for companies and researchers working, fostering and financing tomorrow’s medical science. In this health & biotech marketplace, global investors of any size can invest in non-listed companies via equity-crowdfunding with the most accurate scientific and financial information about every project.